Short interest for NuStar Logistics, L.P. 7.625% Fixed-to-Floating Rate Subordinated Notes due 2043 gives investors a sense of the degree to which investors are betting on the decline of NuStar Logistics, L.P. 7.625% Fixed-to-Floating Rate Subordinated Notes due 2043's stock. Short interest data is updated every two weeks.

NuStar Logistics, L.P. 7.625% Fixed-to-Floating Rate Subordinated Notes due 2043 Stock (NYSE:NSS), Short Interest Report

NuStar Logistics, L.P. 7.625% Fixed-to-Floating Rate Subordinated Notes due 2043

NAPCO Security Technologies, Inc. - Common Stock

NAPCO Security Technologies Inc

NS SOLUTIONS CORP ORD by NS Solutions Corp.

NS Solutions Corp

Willie Nelson and his wife Annie are releasing a new weed-centric cookbook just in time for the holiday season. Out in mid-November,&nbsp;"Willie and Annie Nelson's Cannabis Cookbook: Mouthwatering Recipes and the High-Flying Stories Behind Them" combines the country music icon's love of marijuana and storytelling with Annie's passion for home-cooked meals.
Nelson&#8217;s first cookbook will highlight recipes from his favorite meals over the decades, from munchies consumed on nationwide tours to family dinners cooked at the Nelsons' Spicewood ranch, all served with a spicy story about each of the dishes.
"Drawn from their favorite meals on nationwide tours, at the ranch, at home, and in their favorite cities along the way, these recipes have stories to tell. And what better way to enjoy a good meal than with a high-flying tale and a relaxing buzz?" <a href="https://premierecollectibles.com/nelson">wrote</a> Premiere Collectibles.
"Each recipe provides a cannabis kick to ease the mind as much as the body, making their cookbook an exciting, comforting and lively way to dive into their story, as they draw from meals shared with family, friends and fans alike."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Just announced… Willie &amp; Annie Nelson's Cannabis Cookbook is set to release on 11/12! HIGHly recommend you pre-order now &#x1f343;<a href="https://t.co/26v2qB6ikX">https://t.co/26v2qB6ikX</a> <a href="https://t.co/Hnz0rPd8Mm">pic.twitter.com/Hnz0rPd8Mm</a>
&mdash; Willie Nelson (@WillieNelson) <a href="https://twitter.com/WillieNelson/status/1790466167921914038?ref_src=twsrc%5Etfw">May 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h1 class="wp-block-heading">The Perfect Combo: Comfort Food and Cannabis</h1>
In addition to comfort food such as buffalo wings, chocolate cake and fried chicken, there is an&nbsp;additional chapter providing a full suite of cannabis-infused base ingredients such as cannabutter, finishing oil, simply syrups, sugars, salts and tinctures.
"To be blunt, we think this book will smoke the competition," <a href="https://www.austinmonthly.com/willie-nelson-launching-cannabis-cookbook/">wrote</a> Austin Monthly.
The 256-page "Willie and Annie Nelson's Cannabis Cookbook: Mouthwatering Recipes and the High-Flying Stories Behind Them" is set for release on Nov. 12 via Gallery Books with pre-orders going on now.
Now read: <a href="https://www.benzinga.com/24/05/38826490/cannabis-beverages-at-liquor-stores-largest-wine-retailer-in-us-selling-6byear-adding-thc-to-the-men">Cannabis Beverages At Liquor Stores? Largest Wine Retailer In US, Selling $6B/Year, Adding THC To The Menu</a>
Photo: Benzinga edit of photo by&nbsp;<a href="https://www.flickr.com/people/43996297@N05" target="_blank" rel="noreferrer noopener">Larry Philpot</a>&nbsp;from Indianapolis on Wikimedia Commons and&nbsp;<a href="https://unsplash.com/@fortheloveofsmoke?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Jeff W</a>&nbsp;on&nbsp;<a href="https://unsplash.com/photos/r19PtSh4m7A?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Unsplash</a>

Cannabis

Entertainment

News

Willie Nelson Is Publishing His First-Ever Cannabis Cookbook That Will 'Smoke The Competition'

Stifel analyst Stephen Soock maintains Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) with a Buy and raises the price target from $6 to $6.25.

Price Target

Analyst Ratings

ORLA

Stifel Maintains Buy on Orla Mining, Raises Price Target to $6.25

Trading Ideas

GameStop Shares Resumed Trade

This week, we released the DKI report on AuthID in public and explain the use cases for biometric security. The stock has some near-term catalysts, and the <a href="https://deepknowledgeinvesting.com/authid-auid-full-report/">full report</a> is available on the DKI website. DKI Intern, Andrew Brown, brings up the complicated issue of whether the government should interfere in free markets to &ldquo;help&rdquo; future homebuyers. Ryan Sullivan, a thoughtful wealth advisor, contributes a guest &ldquo;Thing&rdquo; on the case for agricultural commodity investing. A new survey shows that people regret buy now, pay later spending. We&rsquo;re shocked that they&rsquo;re shocked that they then receive monthly bills for the debt that&rsquo;s not being tracked. And I get attacked on Twitter/X by people arguing against things I never said and never did. Some complained that this week in the market was &ldquo;boring&rdquo;, but it was an eventful week at DKI. Ready?
This week, we&rsquo;ll address the following topics:
<ul>
<li>
DKI writes on AuthID (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auid#NASDAQ">AUID</a>) and the case for biometric security.
</li>
<li>
How many single-family homes are Wall Street investors buying? Should Congress do something?
</li>
<li>
Do higher agricultural commodity prices mean paying more at the supermarket or are they an investment opportunity? Ryan Sullivan of <a href="https://www.obpfinancial.com/">Off The Beaten Path Financial</a> provides a guest &ldquo;Thing&rdquo;.
</li>
<li>
A survey of buy now, pay later users reveals a high level of financial stress. Are you surprised?
</li>
<li>
Misunderstood posts and strawman arguments. My analysis doesn&rsquo;t cause the world to change. It does help protect DKI subscribers from bad policy.
</li>
</ul>
Ready for a new week of rejecting strawman arguments? Let&rsquo;s dive in:
<ul>
<li>
AuthID $AUID and the Case for Biometric Security:
</li>
</ul>
Last week, I wrote about being permanently suspended on Twitter/X due to the actions of someone impersonating me. The X support team was responsive and effective in helping me regain control of my account within one day, but it took hours of my time to figure out what was happening and to manage the process. Had I been able to secure my account, name, and image with biometric security, we might have been able to avoid the issue entirely. Now, imagine that the person committing fraud was able to gain access to your work email, your bank account, or your brokerage account. Usernames, passwords, and two factor authentication involving email or text messages are no longer good enough. I believe the next step in securing your identity and accounts will be facial identification. AuthID has a best-in-class .7 second authentication process and a new CEO with a history of building successful sales teams in the industry. DKI&rsquo;s <a href="https://deepknowledgeinvesting.com/authid-auid-full-report/">full report</a> is publicly available on our website.
<img alt="authid-logo.jpg" src="https://www.benzinga.com/files/images/2024/May/15/authid-logo.jpg" style="height:486px; width:624px" />
Fast low-friction authentication is necessary when fraudsters get better every year.
DKI Takeaway:&nbsp; AuthID is a public venture capital company that won&rsquo;t start to produce meaningful revenue until next year. We believe the company presents a <a href="https://deepknowledgeinvesting.com/authid-auid-full-report/">skewed return distribution with huge upside in a growing market</a> meaning you&rsquo;re risking one dollar for the potential to make $10 - $15 in the next five to six years. Near-term expected catalysts include more clear financial reporting, a successful secondary financing, and more customer contract announcements. DKI&rsquo;s report includes a lengthy section detailing the risks in the stock, and is available on our website. The short-sellers in the name list no risks to their thesis, but do like to make personal attacks. We suggest you read both sides, and decide for yourself who has the better case on the company.
<ul>
<li>
Should Congress Stop Wall Street from Buying All the Homes?:
</li>
</ul>
DKI Intern, Andrew Brown, notes that there is increasing concern about big Wall Street firms buying more single-family homes. Home ownership is a core part of the American Dream. While many people like the flexibility and capital preservation of renting, home ownership has created long-term personal and financial stability for millions of families. If big firms with unmatched access to capital buy up all the housing stock, can they turn us all into renters? Lawmakers in many States as well as the US Congress are considering bans on corporate purchase of single-family homes, forcing companies to sell their existing inventory, or imposing additional taxes on large corporations&rsquo; home ownership portfolios. Do you think the government should intervene?
<img alt="freddie_mac_-_large_corporation_buyer_share_.jpg" src="https://www.benzinga.com/files/images/2024/May/15/freddie_mac_-_large_corporation_buyer_share_.jpg" style="height:388px; width:624px" />
The issue isn&rsquo;t as big as some have said. <a href="https://www.freddiemac.com/research/pdf/202203-Note-HomePrices-12.pdf">Chart</a> from Freddie Mac.
DKI Takeaway:&nbsp; This is a heated issue with strong emotions attached. Looking at the chart from Freddie Mac, you can see that large corporate buyer home purchases are a much smaller share of the market than the 40%+ some have claimed. DKI thinks this issue has nuance. We&rsquo;ve recently been shedding light on the struggles young people encounter when they try to buy a home. Wall Street purchase of housing inventory pushes up prices and causes those young people to stay renters for longer. No individual in their 20s or 30s is going to be able to outbid the big firms with near-unlimited access to capital. It&rsquo;s easy to look at the situation and say the government should step in to protect the ability of young people to own instead of rent. But forcing companies to liquidate their assets could establish a risky precedent. In addition, we&rsquo;re accustomed to thinking about this from the point of view of the buyer. Now, imagine you own a home and want to sell and pay off your mortgage. Should the government tell you that it&rsquo;s illegal to sell to the highest bidder? Typically, when the government puts its thumb on the scale for &ldquo;good reasons&rdquo;, we get unpleasant unintended consequences. In general, DKI favors free markets over governmental interference, but this is a tough issue, and we don&rsquo;t know the right answer. What do you think?
<ul>
<li>
Agricultural Commodities Outperforming:
</li>
</ul>
Ryan Sullivan of <a href="https://www.obpfinancial.com/">Off The Beaten Path Financial</a> writes:&nbsp; Do you get surprised at the checkout every time you go to the store? In 2024, agricultural commodity prices have been outpacing all other commodity indices. While many (including DKI) focused on gold breaking new highs, cocoa was up ~280% at its peak this year. Futures prices have fluctuated, but if you are a chocolate lover, then you still have some time to stock up. West Africa exports over 70% of the world&rsquo;s cocoa and has been struggling with a combination of bad weather and disease. The impact of this will hit consumers later this year. This is just one example of a tight agriculture market that is still increasing food prices for all. While inflation is below the 2022 highs, food prices are still increasing (just at a slower rate).
<img alt="obp_financial_-_commodity_comparison_-_may_10th_2024.jpg" src="https://www.benzinga.com/files/images/2024/May/15/obp_financial_-_commodity_comparison_-_may_10th_2024.jpg" style="height:391px; width:624px" />
Commodity markets up this year. Agriculture up more.
DKI Takeaway:&nbsp; Ryan Sullivan continues:&nbsp; Rising global population combined with conflicts and poor weather are leading to higher agriculture prices which leads to higher food prices. While the CPI is increasing at a slower rate for now, a tight labor market also increases food costs. With inflation starting to rise again, this is an area to watch closely as higher fuel prices can cause agricultural prices to quickly spiral. It&rsquo;s always a good idea to have some food stocked up, especially if you like your chocolate! (DKI note:&nbsp; I am a big fan of keeping a large supply of emergency food at home. Worst case is you have some extra tuna fish and chocolate next year.)
<ul>
<li>
The &ldquo;Shocking&rdquo; Stress of Buy Now, Pay Later:
</li>
</ul>
DKI has written about some of the concerning uses of buy now, pay later including people financing the purchase of fast food burgers and their monthly rent. A new poll reveals that 54% of buy now, pay later users spent more than they could afford. Significant percentages of users are falling behind on other lines of credit, have gone into significant debt, and report their spending is out of control. Somehow, 31% were surprised by how much they owe every month to pay off their BNPL loans. I&rsquo;m not sure what&rsquo;s more incredible; that people who borrow money are surprised they have monthly bills to pay back their debt, or that I&rsquo;m surprised by this.
<img alt="bnpl_a.jpg" src="https://www.benzinga.com/files/images/2024/May/15/bnpl_a.jpg" style="height:398px; width:624px" />
There are a lot of people using credit unwisely.
DKI Takeaway:&nbsp; We live in a consumer culture, and inflation has been tough on all of us. However, if you&rsquo;re already employed, the only sustainable option is to reduce spending. Many people are already experiencing personal financial problems. From the point of view of someone who looks at a lot of macro data, there&rsquo;s another problem. BNPL debt is often not reported as consumer debt. This means that when you see data showing higher credit usage by consumers, you&rsquo;re not seeing all of it. Total credit card debt is at an all-time high and that&rsquo;s not counting BNPL.
<ul>
<li>
Misunderstood Posts and Strawman Arguments:
</li>
</ul>
Last week, I was suspended from Twitter/X due to the actions of an imposter. This week, I got hate mail for things I never said. As <a href="https://twitter.com/RobbFahrion">Robb Fahrion</a> joked in last week&rsquo;s 5 Things video, I&rsquo;m &ldquo;micro-famous&rdquo;. People took issue with my posts noting that work from home was a problem for the owners of office space and showing that government debt was increasing faster than GDP. I was accused of trying to force people back into the office, of donating to President Trump&rsquo;s campaign, and of trying to get tax breaks for billionaires. Here are the facts: I work from all over the world, and never intend for DKI to have an office. I have never donated to a Presidential campaign. And billionaires have plenty of influence and lobbyists. They don&rsquo;t need my help. So, what&rsquo;s going on?
<img alt="debt_vs_gdp_growth_1.jpg" src="https://www.benzinga.com/files/images/2024/May/15/debt_vs_gdp_growth_1.jpg" style="height:397px; width:624px" />
This graph seemed to upset a lot of people. Regardless of their feelings, it shows that government spending is destroying value.
DKI Takeaway:&nbsp;These insults are all strawman arguments and rely on arguing against things I never said. Observing an economic problem doesn&rsquo;t mean that I&rsquo;m in favor of the policies that caused that problem, or that my analysis caused it to happen. It is my job to figure out what can go wrong and come up with strategies to protect DKI subscribers from what&rsquo;s coming, or even to make money from it. Massive government spending led to the inflation we&rsquo;ve experienced the past few years. I recognized it early, and told DKI subscribers I was buying Bitcoin, gold, and energy (oil and uranium). They&rsquo;ve all been hugely profitable investments. None of that means that I&rsquo;m in favor of too much government spending, that I want to cut your favorite government program, or that I can change the practices of our government. Angry people can type angry things hidden at their keyboards. At DKI, we&rsquo;re going to stay calm and cerebral, do a lot of original research, and try to make money for our clients and subscribers regardless of market conditions or governmental policies.
Information contained in this report, and in each of its reports, is believed by Deep Knowledge Investing (&ldquo;DKI&rdquo;) to be accurate and/or derived from sources which it believes to be reliable; however, such information is presented without warranty of any kind, whether express or implied.&nbsp; DKI makes no representation as to the completeness, timeliness, accuracy or soundness of the information and opinions contained therein or regarding any results that may be obtained from their use.&nbsp;The information and opinions contained in this report and in each of our reports and all other DKI Services shall not obligate DKI to provide updated or similar information in the future, except to the extent it is required by law to do so.&nbsp;
The information we provide in this and in each of our reports, is publicly available. This report and each of our reports are neither an offer nor a solicitation to buy or sell securities. All expressions of opinion in this and in each of our reports are precisely that. Our opinions are subject to change, which DKI may not convey. DKI, affiliates of DKI or its principal or others associated with DKI may have, taken or sold, or may in the future take or sell positions in securities of companies about which we write, without disclosing any such transactions.
None of the information we provide or the opinions we express, including those in this report, or in any of our reports, are advice of any kind, including, without limitation, advice that investment in a company&rsquo;s securities is prudent or suitable for any investor. In making any investment decision, each investor should consult with and rely on his or its own investigation, due diligence and the recommendations of investment professionals whom the investor has engaged for that purpose.&nbsp;
In no event shall DKI be liable, based on this or any of its reports, or on any information or opinions DKI expresses or provides for any losses or damages of any kind or nature including, without limitation, costs, liabilities, trading losses, expenses (including, without limitation, attorneys&rsquo; fees), direct, indirect, punitive, incidental, special or consequential damages.

Government

Markets

General

AUID

5 Things To Know In Investing This Week: The That's Not What I Said Issue

Stifel analyst Stephen Soock maintains MAG Silver (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#AMEX">MAG</a>) with a Buy and raises the price target from $20.25 to $20.5.

Stifel Maintains Buy on MAG Silver, Raises Price Target to $20.5

Scotiabank analyst Francisco Suarez downgrades Central North Airport Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMAB#NASDAQ">OMAB</a>) from Sector Perform to Sector Underperform.

Downgrades

Grupo Aeroportuario del Centro NorteB de CV

OMAB

Scotiabank Downgrades Central North Airport Gr to Sector Underperform

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares were trading higher following a report indicating Elon Musk&#8216;s artificial intelligence startup, xAI, is nearing a $10 billion deal to <a href="https://www.benzinga.com/markets/equities/24/05/38850447/whats-going-on-with-oracle-corporation-shares-wednesday">rent Oracle&#8217;s AI servers</a>.
This potential deal, if finalized, would make xAI one of Oracle&#8217;s largest customers, underscoring the significance of the contract for Oracle's cloud infrastructure business. 
Oracle Chairman Larry Ellison had previously mentioned their collaboration with xAI, highlighting the increasing demand for computing power from Musk&#8217;s company. There are ongoing negotiations, though there is no guarantee that the deal will be signed, <a href="https://finance.yahoo.com/news/elon-musks-xai-nears-10-161135935.html">reported</a> The Information.
<h2 class="wp-block-heading">xAI Deal &#8211; An Oracle Strategy To Rival AI Capabilities Of OpenAI and Google</h2>
Musk&#8217;s xAI has been actively seeking funding, recently closing a $6 billion round that values the company at around $18 billion. 
This move is part of Musk&#8217;s broader strategy to rival the AI capabilities of companies like OpenAI and Google. Oracle&#8217;s involvement in these high-stakes discussions reflects its growing role in the AI and cloud computing sectors. 
Furthermore, Oracle&#8217;s recent update to its database technology aims to enhance its utility in AI applications, reinforcing its commitment to staying at the forefront of technological advancements.
The stock has gained 15.13% in 2024 and is up 24.28% over the past year.
<h2 class="wp-block-heading">Bullish Momentum Surrounds Oracle Stock</h2>
From a technical analysis perspective, Oracle&#8217;s stock is demonstrating strong bullish momentum.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="628" height="453" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/15101855/Screenshot-2024-05-15-at-6.19.21-PM.png" alt="" class="wp-image-339573" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/15101855/Screenshot-2024-05-15-at-6.19.21-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/15101855/Screenshot-2024-05-15-at-6.19.21-PM-300x216.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart: Benzinga Pro</a>
The current share price is $121.10, which is above its 8-day simple moving average (SMA) of $118.16, the 20-day SMA of $116.44, and the 50-day SMA of $120.61. These indicators suggest a continued upward trend. 
Additionally, the stock is trading above its 200-day SMA of $113.67, providing a strong bullish signal in the longer term.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="628" height="453" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/15102116/Screenshot-2024-05-15-at-6.20.14-PM.png" alt="" class="wp-image-339580" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/15102116/Screenshot-2024-05-15-at-6.20.14-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/15102116/Screenshot-2024-05-15-at-6.20.14-PM-300x216.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart: Benzinga Pro</a>
However, some caution is warranted. The Moving Average Convergence Divergence (MACD) indicator is at -0.19, suggesting potential selling pressure. However, it recently crossed over the signal line, which is at -0.89 currently, showing some positive momentum among traders of the stock.
The Relative Strength Index (RSI) is at 59.86, which is approaching the overbought threshold of 70. This could indicate a potential pullback if the RSI continues to rise and enters overbought territory.
The Bollinger Bands analysis is mixed. The stock has recently moved from the lower band to the upper band, driven by the &#8216;Musk&#8217;s xAI surge.&#8217; The surge took the stock beyond the upper limits, indicating possible overvaluation.
<h2 class="wp-block-heading">Oracle Stock Analysts See An Average 20% Upside</h2>
<a href="https://www.benzinga.com/quote/ORCL/analyst-ratings">Analysts consensus rates</a> the stock a Buy. Multiple analyst ratings received in March have upgraded their price targets on Oracle stock with their price targets largely between $130 &#8211; $145 a share. The price targets imply an average 20% upside from current levels.
Oracle&#8217;s stock is currently experiencing bullish momentum, supported by significant corporate developments and positive technical indicators. 
However, investors should remain cautious due to potential overbought conditions, which suggest varying degrees of risk and uncertainty. Balancing these factors will be crucial for investors considering Oracle&#8217;s stock amid its evolving role in the AI and cloud computing landscape.
ORCL Price Action: Oracle stock was up 0.5% at $121.50 at the time of publication Wednesday.
Now Read: <a href="https://www.benzinga.com/general/social-media/24/05/38849057/gamestop-amc-stock-in-freefall-wednesday-is-2024-meme-stock-rally-over">GameStop, AMC Stock In Freefall Wednesday: Is 2024 Meme Stock Rally Over?</a>
Photo: Shutterstock

Technicals

Tech

ORCL

Oracle Stock Climbs On Reports Of Deal With Musk's xAI: Is There More Upside Ahead?

HC Wainwright &amp; Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) with a Buy and lowers the price target from $18 to $6.

AEON

HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $6

Raymond James analyst David Hicks reinstates Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Market Perform.

Initiation

SNDR

Raymond James Reinstates Market Perform on Schneider National

Raymond James analyst Felix Boeschen reinstates Marten Transport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRTN#NASDAQ">MRTN</a>) with a Outperform and announces $20 price target.

MRTN

Raymond James Reinstates Outperform on Marten Transport, Announces $20 Price Target

Wednesday,&nbsp;Takeda Pharmaceutical Co Ltd&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) dengue vaccine&nbsp;<a target="_blank" href="https://www.who.int/news/item/15-05-2024-who-prequalifies-new-dengue-vaccine" rel="noreferrer noopener">received</a>&nbsp;World Health Organization&#8217;s (WHO) prequalification.&nbsp;
TAK-003 is the second dengue vaccine to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/04/31935884/united-nations-specialized-agency-in-preliminary-talks-with-takeda-for-dengue-vaccine-currently-u" rel="noreferrer noopener">be prequalified by WHO</a>.&nbsp;
The prequalification makes it eligible for procurement by United Nations agencies like UNICEF and&nbsp;Pan&nbsp;American Health Organization (PAHO).
The vaccine, dubbed Qdenga, is approved in Indonesia, Brazil, the European Union (EU), Iceland, the U.K., Norway, and Lichtenstein.&nbsp;
Developed by Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.&nbsp;
WHO recommends using TAK-003 in children aged 6–16 in settings with high dengue burden and transmission intensity.&nbsp;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38740197/japans-takeda-pharma-outlines-900m-overhaul-to-boost-growth-as-2023-profit-fall-over-50" rel="noreferrer noopener">Japan&#8217;s Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%</a>.
The vaccine should&nbsp;be administered&nbsp;in a 2-dose schedule with a 3-month interval between doses.&nbsp;
Following discussions with the FDA in July last year,&nbsp;Takeda&nbsp;voluntarily&nbsp;withdrew its marketing application for TAK-003, citing data collection issues.
The drugmaker said the&nbsp;future&nbsp;plan for the candidate, TAK-003, in the U.S. would be further evaluated, given the need for travelers and those living in dengue-endemic areas of the U.S.,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33195839/takeda-withdraws-fda-application-for-dengue-vaccine-candidate-on-data-disagreement" rel="noreferrer noopener">such as Puerto Rico.</a>
In February, Takeda and&nbsp;Biological E. Limited&nbsp;<a target="_blank" href="https://www.takeda.com/newsroom/newsreleases/2024/collaboration-to-accelerate-access-to-dengue-vaccine/" rel="noreferrer noopener">partnered</a>&nbsp;to expedite the distribution of Qdenga.&nbsp;These&nbsp;vaccines will be available for government procurement in dengue-endemic countries&nbsp;by 2030.
Biological E. plans to scale up to produce 50 million doses annually, supporting Takeda&#8217;s goal of producing 100 million doses a year within the next decade. This partnership will leverage Takeda&#8217;s existing manufacturing in Singen, Germany, and its collaboration with&nbsp;IDT Biologika GmbH.
The WHO prequalification list also includes the CYD-TDV vaccine against dengue developed by&nbsp;Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).&nbsp;
Dengue is a vector-borne disease transmitted by the bite of an infected mosquito.&nbsp;
It&nbsp;is estimated&nbsp;that over 100-400 million cases of dengue occur worldwide each year and that 3.8 billion people live in dengue-endemic countries, most of which are in Asia, Africa, and the Americas.&nbsp;
The&nbsp;largest&nbsp;number of dengue cases reported was in 2023, with the WHO Region of the Americas reporting 4.5&nbsp;million cases and 2300 deaths.&nbsp;
Price Action: TAK shares are trading at $13.45 at last check Wednesday.
Photo by Wolfgang Hasselmann on Unsplash

Biotech

Large Cap

Health Care

Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement

During the last three months, 21 analysts shared their evaluations of First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $242.9, a high estimate of $356.00, and a low estimate of $194.00. This current average represents a 0.3% decrease from the previous average price target of $243.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1715796150_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive First Solar. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$228.00</td>
<td>$227.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$356.00</td>
<td>$359.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$252.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$271.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Dushyant Ailani</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$211.00</td>
<td>$209.50</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$209.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$248.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Brian Kinstlinger</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$268.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Sean Morgan</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$227.00</td>
<td>-</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$227.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Markus Leistner</td>
<td>DZ Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$205.00</td>
<td>-</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Sean Milligan</td>
<td>Janney Montgomery Scott</td>
<td>Announces</td>
<td>Buy</td>
<td>$236.00</td>
<td>-</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$194.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$258.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$258.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>-</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$268.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to First Solar. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Solar compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of First Solar's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of First Solar's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FSLR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Solar analyst ratings.</a>
<h2>All You Need to Know About First Solar</h2>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
<h3>Understanding the Numbers: First Solar's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: First Solar's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 15.58%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: First Solar's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 30.14%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): First Solar's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.38% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): First Solar's ROA excels beyond industry benchmarks, reaching 3.5%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.09, First Solar adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FSLR

Deep Dive Into First Solar Stock: Analyst Perspectives (21 Ratings)

In the preceding three months, 5 analysts have released ratings for Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.6, with a high estimate of $65.00 and a low estimate of $55.00. Experiencing a 10.38% decline, the current average is now lower than the previous average price target of $66.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1715796142_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Allegiant Travel among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helane Becker</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Atul Maheswari</td>
<td>UBS</td>
<td>Announces</td>
<td>Sell</td>
<td>$58.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allegiant Travel. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allegiant Travel compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Allegiant Travel's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Allegiant Travel analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Allegiant Travel</h2>
Allegiant Travel Co provides travel services in the United States. It sells air transportation on a stand-alone basis or bundled with air-related and third-party services and products. Customers may also purchase fixed-fee flying arrangements to receive charter service on a year-round and ad hoc basis. Additionally, customers may purchase hotel rooms, ground transportation, and other attractions (for example, entertainment show tickets) to accommodate a trip. The company's operating segment includes Airline, Sunseeker Resort, and other non-airlines. Customers purchase travel tickets at airport ticket counters, online, or through its telephone reservation center.
<h3>Financial Insights: Allegiant Travel</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Allegiant Travel's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 1.03%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.1%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Allegiant Travel's ROA stands out, surpassing industry averages. With an impressive ROA of -0.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.78.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGT

Allegiant Travel Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and maintains $17 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target

GameStop Shares Halted On Circuit Breaker To The Upside, Stock Now Down -20.3%

Analysts' ratings for AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $75.14, a high estimate of $87.00, and a low estimate of $65.00. A decline of 8.56% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1715796118_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of AMN Healthcare Services among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AMN Healthcare Services. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AMN Healthcare Services compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of AMN Healthcare Services's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AMN Healthcare Services's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AMN Healthcare Services analyst ratings.</a>
<h2>All You Need to Know About AMN Healthcare Services</h2>
AMN Healthcare Services is one of the largest healthcare staffing company in the United States. In 2023, it offered more than 13,000 nurses and allied healthcare full-time workers with provider clients nationwide. About two thirds of its business is generated from its temporary nursing division; the other third is generated from its physician placement and technology-backed workplace solutions divisions.
<h3>Financial Milestones: AMN Healthcare Services's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: AMN Healthcare Services's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -27.11%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AMN Healthcare Services's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.06%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): AMN Healthcare Services's ROA stands out, surpassing industry averages. With an impressive ROA of 0.6%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.54.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For AMN Healthcare Services

Raymond James analyst Felix Boeschen reinstates Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) with a Outperform and announces $205 price target.

LSTR

Raymond James Reinstates Outperform on Landstar System, Announces $205 Price Target

Financial giants have made a conspicuous bullish move on Southwest Airlines. Our analysis of options history for Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $102,700, and 6 were calls, valued at $166,822.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.5 to $32.5 for Southwest Airlines over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Southwest Airlines's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Southwest Airlines's significant trades, within a strike price range of $22.5 to $32.5, over the past month.
<h3>Southwest Airlines Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715796079_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.1</td>
<td>$1.09</td>
<td>$1.1</td>
<td>$22.50</td>
<td>$55.0K</td>
<td>11.4K</td>
<td>500</td>
</tr>
<tr>
<td>LUV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.56</td>
<td>$0.52</td>
<td>$0.53</td>
<td>$22.50</td>
<td>$47.7K</td>
<td>2.1K</td>
<td>908</td>
</tr>
<tr>
<td>LUV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.84</td>
<td>$0.82</td>
<td>$0.84</td>
<td>$32.50</td>
<td>$34.6K</td>
<td>1.4K</td>
<td>3.9K</td>
</tr>
<tr>
<td>LUV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.85</td>
<td>$0.83</td>
<td>$0.85</td>
<td>$32.50</td>
<td>$28.2K</td>
<td>1.4K</td>
<td>1.9K</td>
</tr>
<tr>
<td>LUV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.85</td>
<td>$3.75</td>
<td>$3.75</td>
<td>$32.50</td>
<td>$26.6K</td>
<td>863</td>
<td>71</td>
</tr>
</tbody>
</table>

<h3>About Southwest Airlines</h3>
Southwest Airlines is the largest domestic air carrier in the United States by passengers boarded. Southwest operates over 800 aircraft in an all-Boeing 737 fleet. Despite offering some longer routes and a few perks for business travelers, the airline predominantly specializes in short-haul, leisure flights operated in a single, open-seating cabin configuration in a point-to-point network.
After a thorough review of the options trading surrounding Southwest Airlines, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Southwest Airlines</h3>
<ul>
<li>With a volume of 4,440,520, the price of LUV is down -0.84% at $27.89. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 71 days.</li>
</ul>
<h3>Professional Analyst Ratings for Southwest Airlines</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $25.76.
<ul>
<li>In a cautious move, an analyst from HSBC downgraded its rating to Hold, setting a price target of $27. </li>
<li>An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $30. </li>
<li>An analyst from Jefferies has revised its rating downward to Underperform, adjusting the price target to $20. </li>
<li>Maintaining their stance, an analyst from TD Cowen continues to hold a Hold rating for Southwest Airlines, targeting a price of $25. </li>
<li>An analyst from Bernstein persists with their Market Perform rating on Southwest Airlines, maintaining a target price of $26. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Southwest Airlines options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Southwest Airlines's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CVX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Chevron.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 50%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $161,679, and 10 are calls, for a total amount of $474,280.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $170.0 for Chevron, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Chevron's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Chevron's substantial trades, within a strike price spectrum from $90.0 to $170.0 over the preceding 30 days.
<h3>Chevron Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715796074_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$2.78</td>
<td>$2.62</td>
<td>$2.78</td>
<td>$160.00</td>
<td>$83.1K</td>
<td>13.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$7.5</td>
<td>$7.4</td>
<td>$7.45</td>
<td>$160.00</td>
<td>$74.5K</td>
<td>1.5K</td>
<td>9</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.4</td>
<td>$8.3</td>
<td>$8.41</td>
<td>$155.00</td>
<td>$63.0K</td>
<td>473</td>
<td>286</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$0.5</td>
<td>$0.49</td>
<td>$0.5</td>
<td>$162.50</td>
<td>$58.2K</td>
<td>1.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$7.8</td>
<td>$7.65</td>
<td>$7.7</td>
<td>$160.00</td>
<td>$57.7K</td>
<td>1.5K</td>
<td>143</td>
</tr>
</tbody>
</table>

<h3>About Chevron</h3>
Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.1 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.8 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2023 stood at 11.1 billion barrels of oil equivalent, including 6.0 billion barrels of liquids and 30.4 trillion cubic feet of natural gas.
<h3>Present Market Standing of Chevron</h3>
<ul>
<li>With a trading volume of 3,963,400, the price of CVX is down by -0.29%, reaching $163.13.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 72 days from now.</li>
</ul>
<h3>What The Experts Say On Chevron</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $182.6.
<ul>
<li>Consistent in their evaluation, an analyst from TD Cowen keeps a Hold rating on Chevron with a target price of $160. </li>
<li>An analyst from HSBC has decided to maintain their Buy rating on Chevron, which currently sits at a price target of $178. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Chevron, targeting a price of $204. </li>
<li>Maintaining their stance, an analyst from Mizuho continues to hold a Buy rating for Chevron, targeting a price of $205. </li>
<li>An analyst from Truist Securities has decided to maintain their Hold rating on Chevron, which currently sits at a price target of $166. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Chevron, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Chevron

BofA Securities&nbsp;analyst Robert F. Ohmes&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/BBY/analyst-ratings" rel="noreferrer noopener">reiterated an Underperform</a>&nbsp;rating on the shares of&nbsp;Best Buy Co Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a price target of $70.00.
Best Buy&nbsp;is expected&nbsp;to report first-quarter FY25&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">earnings on May 30.</a>
The analyst&#8217;s model assumes an enterprise comparable sales decline of (5)%, a modest deceleration from (4.8)% reported in the fourth quarter.
Spending&nbsp;at consumer electronics (CE)&nbsp;&amp;&nbsp;hobby retailers remains negative but improved to (7.2)% in the first quarter vs. (8.6)% in the fourth quarter, per BAC aggregated credit&nbsp;&amp;&nbsp;debit card data, noted the analyst.
While laptop units trended positive in F4Q and Feb, the analyst does not expect&nbsp;innovation in laptops&nbsp;to spur a replacement cycle this year.
The analyst anticipates continued weakness in the appliance category given y/y declines in pricing&nbsp;and&nbsp;higher&nbsp;retail promotions&nbsp;and&nbsp;market share pressures from competitor&nbsp;Costco Wholesale Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>).
A recovery in BBY&#8217;s monthly active users on&nbsp;mobile&nbsp;app suggests an improvement in domestic digital comps in the first quarter, opined the analyst.
The analyst forecasts gross margin expansion in FY25, given profitability improvements to membership program which are expected to&nbsp;be&nbsp;another 45 basis points&nbsp;benefit in FY25.
BBY has taken steps to reposition its labor force in 1H to reflect recent sales trends and right-size areas where it expects to see lower volume, said the analyst.
The analyst maintains&nbsp;Underperform&nbsp;rating, given challenging industry trends and uncertainty around the timing of a replacement cycle.&nbsp;
BBY stock has gained more than 1% in the last 12 months.&nbsp;Investors can&nbsp;gain access to&nbsp;the stock via&nbsp;Invesco S&amp;P Ultra Dividend Revenue ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDIV#NYSE">RDIV</a>) and&nbsp;Invesco S&amp;P 500 High Dividend Low Volatility ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHD#NYSE">SPHD</a>).
Price Action: BBY shares are trading higher by 1.97% at $74.13 at the last check Wednesday.
Image via Shutterstock